SGMO Sangamo Therapeutics Inc.

9.71
0  0%
Previous Close 9.71
Open
Price To Book 3.41
Market Cap 1,120,163,719
Shares 115,361,866
Volume 215
Short Ratio
Av. Daily Volume 1,357,828

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 FVIII levels 140% and 94% of normal (or 93% and 65%) depending on measure.
SB-525
Hemophilia A
Phase 1/2 further data due 4Q 2019.
ST-400
beta-thalassemia
Phase 1/2 longer-term safety and biochemical data due in 2019.
SB-318
MPS Type 1
Phase 1/2 data due 2019.
SB-FIX
Hemophilia B
Phase 1/2 updates during 2019.
SB-913 - CHAMPIONS
MPS Type 2
Phase 1/2 trial to be initiated 2019.
ST-920
Fabry disease

Latest News

  1. Here’s What Hedge Funds Think About Sangamo Therapeutics, Inc. (SGMO)
  2. Edited Transcript of SGMO earnings conference call or presentation 8-May-19 9:00pm GMT
  3. Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
  4. A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last?
  5. Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences
  6. Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
  7. Sangamo Biosciences Inc (SGMO) Q1 2019 Earnings Call Transcript
  8. Here's Why Sangamo Therapeutics Fell as Much as 13.6% Today
  9. What You Need to Know About Sangamo Therapeutics' Q1 Earnings Results
  10. Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
  11. Sangamo: 1Q Earnings Snapshot
  12. Sangamo Therapeutics Reports First Quarter 2019 Financial Results
  13. Sangamo Therapeutics, Inc. to Host Earnings Call
  14. If You Had Bought Sangamo Therapeutics (NASDAQ:SGMO) Stock Three Years Ago, You Could Pocket A 93% Gain Today
  15. Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
  16. Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock?
  17. Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy
  18. What’s Expected for Sangamo’s and Amarin’s EPS
  19. Comparing Sangamo’s and Amarin’s Revenue Growth